Table 1 Clinical trials investigating anti-CTLA-4 antibodies in head and neck squamous cell carcinoma (HNSCC)
Trial | Drug | Study phase | Tumor entity |
|---|---|---|---|
NCT04080804 | Neoadjuvant nivolumab (anti-PD-1) alone or in combination with relatlimab (anti-LAG3) or ipilimumab (anti-CTLA-4) | II | Resectable HNSCC |
NCT03624231 | Durvalumab (anti-PD-L1) + tremelimumab (anti-CTLA-4) + radiotherapy versus durvalumab (anti-PD-L1) + radiotherapy | II | Non-resectable locally advanced HPV negative HNSCC |
NCT04326257 | Nivolumab (anti-PD-1) + ipilimumab (anti-CTLA-4) or relatlimab (anti-LAG3) | II | Recurrent and/or metastastic HNSCC that have progressed on prior immunotherapy |
NCT03212469 | Durvalumab (anti-PD-L1) + tremelimumab (anti CTLA-4) in combination with stereotactic body radiotherapy | I/II | HNSCC |
NCT03799445 | Ipilimumab (anti-CTLA-4), nivolumab (anti-PD-1), and radiation therapy | II | HPV positive advanced oropharyngeal squamous cell carcinoma |